• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    9/13/23 5:31:44 PM ET
    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    Gainers

    • Infinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 15.55% to $1.04. The company's market cap stands at $2.1 million.
    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 14.94% to $0.01.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 11.45% to $1.46. Today's trading volume for this security ended up closing at 582.8K shares, which is 6319.1 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.3 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock rose 10.86% to $0.25. Trading volume for this security closed at 94.4 million, accounting for 886.9% of its average full-day volume over the last 100 days. The company's market cap stands at $5.0 million.
    • NanoString Technologies (NASDAQ:NSTG) stock rose 10.55% to $1.99. The company's market cap stands at $94.6 million.

    Losers

    • Kiromic BioPharma (NASDAQ:KRBP) shares declined by 51.0% to $0.71 during Wednesday's after-market session. At the close, Kiromic BioPharma's trading volume reached 65.0K shares. This is 90.6% of its average volume over the last 100 days.
    • OKYO Pharma (NASDAQ:OKYO) stock decreased by 25.26% to $1.48. At the close, OKYO Pharma's trading volume reached 62.9K shares. This is 26.7% of its average volume over the last 100 days. The company's market cap stands at $37.8 million.
    • Bionomics (NASDAQ:BNOX) stock declined by 22.35% to $1.39. Today's trading volume for this security ended up closing at 226.7K shares, which is 112.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $11.3 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares decreased by 12.05% to $0.73. At the close, Impel Pharmaceuticals's trading volume reached 281.1K shares. This is 31.6% of its average volume over the last 100 days. The company's market cap stands at $17.3 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock fell 8.16% to $5.18. This security traded at a volume of 343.5K shares come close, making up 450.3% of its average volume over the last 100 days. The company's market cap stands at $7.4 million.
    • Joint (NASDAQ:JYNT) stock decreased by 7.49% to $8.65. The market value of their outstanding shares is at $126.9 million. The company's, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $BNOX
    $CELZ
    $IMPL

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    More analyst ratings

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

    BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.

    4/7/26 8:30:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

    LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, DC. The SAB meeting, scheduled to take place alongside the conference, will bring together prominent corneal and ocular surface disease specialists to review clinical data for the company's lead candidate, urcosimod and

    4/7/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

    JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previously announced acquisition of Recipharm Israel Ltd. and related commercial collaboration with Recipharm, this reorganization represents a structural transformation of the Company's operating model, designed to enhance capital efficiency, improve operational focus and position each business

    4/6/26 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    SEC Filings

    View All

    SEC Form DEFA14A filed by Avalo Therapeutics Inc.

    DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

    4/10/26 4:02:49 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Avalo Therapeutics Inc.

    DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

    4/10/26 4:01:30 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by The Joint Corp.

    DEFA14A - JOINT Corp (0001612630) (Filer)

    4/7/26 4:24:22 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Jobson Charles E bought $130,874 worth of Common (15,397 units at $8.50), increasing direct ownership by 0.94% to 1,645,294 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/17/26 5:36:26 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $3,898 worth of Common (448 units at $8.70), increasing direct ownership by 0.03% to 1,639,597 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/13/26 5:16:01 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $174,780 worth of Common (17,478 units at $10.00), increasing direct ownership by 1% to 1,639,149 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    1/27/26 8:45:38 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/8/26 4:51:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sullivan Christopher Ryan

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:14:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:13:22 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Bionomics Limited

    SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)

    11/14/24 3:25:19 PM ET
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNOX
    $CELZ
    $IMPL
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care